抄録
The laboratory and clinical investigations with a new penicillin derivative, pivampicillin, were performed with the results which may lead to the following conclusions.
1) Concentration in blood : Blood concentration after a single oral dose of pivampicillin 250mg in healthy adults was 2.1mcg/ml at 30 minutes after the dose, 3.4mcg /ml, a peak at 1 hour, 1.6mcg/ml at 4 hours and 0.6 mcg/ml at 6 hours. The maximal concentration reached 9.3mcg/ml on the average 30 minutes after a single oral administration of 500mg in healthy adults, and the concentration was still 1.4mcg/ml in 6 hours after the administration.
2) Concentration in tissues : At 6 hours after a single oral dose of pivampicillin 500mg, the concentration in the tissues of tonsilla was 2.5mcg/g as against 10 and 12mcg/ml in serum, and the concentration in the tissues of mucous membrane of maxillary sinusitis was 1.5mcg/g as compared with 10.7mcg/ml in serum.
3) Clinical results : Pivampicillin was given orally in 40 cases with typical infections in the field of otorhinolaryngology. As a result, there were 10 “Excellent” responses, 25 “Good” responses, 3 “Fair” responses, and 2 “Poor” responses. Pivampicillin was effective in 35 cases (87.5%).
4) Side effect : No side effect was observed when pivampicillin was clinically used. No unfavourable influence was noticed on hepatic function, serum electrolyte nor auditory acuity.
